AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Injury is physiological damage to an organism. The response to injury, whether in humans, in other animals, in plants, in fungi, or in single-celled eukaryotes such as choanoflagellates, is substantially shared, implying that the mechanisms are ancient. Injuries can be caused in many ways, including mechanical trauma, toxins, interactions with other organisms, or abiotic factors in the environment. In many animal taxa, injury prompts an inflammatory response that initiates wound healing. In both plants and animals, substances are released to help occlude the wound, limiting fluid loss and the entry of pathogens. Many organisms secrete antimicrobial chemicals, which limit wound infection; animals have immune responses for the same purpose. Both plants and animals have mechanisms of regrowth that may result in complete or partial healing of the injury.
Ranked among the top three overall in the fDi Intelligence Global Free Zones of the Year Awards 2024. Ranked among the top two worldwide in the “Sustainable Zones” category of the fDi Intelligence Global Free Zones of the Year Awards 2024. UN Investment Promotion Award 2023 for supporting clean tech and renewable energy. Industrial Strategic Partner Award 2024 from the UAE Ministry of Industry and Advanced Technology (MoIAT). EFQM 6-Star Certification for operational excellence and sustainable development.
=== United States === The United States Code of Federal Regulations standard for blue cheese specifies a minimum milkfat content of 50 percent, and maximum moisture of 46 percent. Optional ingredients permitted include food coloring to neutralize the yellowish tint of the cheese, benzoyl peroxide bleach, and vegetable wax for coating the rind.
=== Local offices === Since his time with the Winston-Salem Cardinals, Mizell had lived in Midway, North Carolina, right outside of Winston-Salem. After retiring as an active player, Mizell became a broadcaster for the Winston-Salem Red Sox. He also worked in sales and public relations for Pepsi-Cola until 1967. Dick Groat, Mizell's teammate on the Pirates, recalled that "as a ballplayer, he wasn't political – players didn't really talk politics." However, Mizell entered North Carolina politics in the 1960s. He was elected to the Davidson County Board of Commissioners in 1966, an election that saw the Republicans gain control of all the local offices. Mizell served as the chairman of the board for two years. In 1968, he attempted to arrange a meeting between the Board of Commissioners and District Highway Commissioner George Hundley to discuss the State Highway Department's response to petitions for work on local roads.
=== Marriage === Seligman writes: "Unlike money, which has at most a small effect, marriage is robustly related to happiness... In my opinion, the jury is still out on what causes the proven fact married people are happier than unmarried people." (pp. 55–56). Married persons report higher levels of happiness and well-being than single people. Other data has shown a spouse's happiness depends on the happiness of their partner. When asked, spouses reported similar happiness levels to each other. The data also shows the spouses' happiness level fluctuates similarly to one another. If the husband is having a bad week, the wife will similarly report she had a bad week. There is little data on alternatives like polyamory, although one study stated wife order in polygyny did not have a substantial effect on life or marital satisfaction over all. This study also found younger wives were happier than older wives. On the other hand, at least one large study in Germany found no difference in happiness between married and unmarried people. Studies have shown that married couples are consistently happier and more satisfied with their life than those who are single. Some research findings have indicated that marriage is the only real significant bottom-up predictor of life satisfaction for men and women, and that those people who have a higher life satisfaction prior to marriage, tend to have a happier marriage. Self-reported satisfaction typically drops as the years of marriage roll on, particularly for couples who have children compared to those who do not.
Sources: en.wikipedia.org
Immune-mediated causes could include transient factors as in Mycoplasma pneumoniae infection (cold agglutinin disease) or permanent factors as in autoimmune diseases like autoimmune hemolytic anemia (itself more common in diseases such as systemic lupus erythematosus, rheumatoid arthritis, Hodgkin's lymphoma, and chronic lymphocytic leukemia). Spur cell hemolytic anemia Any of the causes of hypersplenism (increased activity of the spleen), such as portal hypertension. Acquired hemolytic anemia is also encountered in burns and as a result of certain infections (e.g. malaria). Lead poisoning or poisoning by arsine or stibine causes non-immune hemolytic anemia. Runners can develop hemolytic anemia due to "footstrike hemolysis", the destruction of red blood cells in feet at foot impact. Low-grade hemolytic anemia occurs in 70% of prosthetic heart valve recipients, and severe hemolytic anemia occurs in 3%.
Episode Two features no new weapons. Instead, Valve explored further uses for the gravity gun, with which the player can pick up and throw large objects. They introduced more varied gravity gun "ammunition", such as logs, flares, and half-height butane tanks, which are easier to aim than full-size fuel drums. Near the end of the game, the player uses "Magnusson Devices", which designer Dario Casali described as a "sticky bomb that you fire at a Strider's underbelly that will draw power from the Strider's internal power source". The player uses the gravity gun to attach the bombs to tripodal enemy Striders; the bombs detonate when fired upon with any other of the player's weapons, instantly destroying the target. The Hunter escorts prioritize them as targets, either destroying them in the player's grasp or shooting already-attached ones off.
=== Visualization === Thyrotropes appear basophilic in histological preparations. In the image displayed on the right, thyrotropes are the cells with the bluish-purple cytoplasm and the dark purple nucleus. Normal morphology of these cells is characterized by a round shape. However, these cells are best displayed under light microscopy performed following immunohistochemistry with TSH. This specific type of imaging allows for the visualization of the location of thyrotrophs in the anterior pituitary gland. Thyrotropic cells are clustered together in the anteromedial region of the gland.
They selected a site where the Italian trenches were sheltered in a deep valley so that a gas cloud would persist. The following Battle of Caporetto broke the Italian lines, and the Central Powers overran much of northern Italy. That summer Hahn was accidentally poisoned by phosgene while testing a new model of gas mask. At the end of the war he was in the field in mufti on a secret mission to test a pot that heated and released a cloud of arsenicals.
== Sources == Hyaluronic acid can be made through three main processes: Animal sources, Microbial hyaluronic acid production and chemical synthesis. HA was originally extracted from bovine vitreous humor (gel from a cows eye) by Meyer and Palmer in 1934. HA was then also isolated from Pig skin, Human skin and rooster’s comb. The most common animal source is rooster’s comb due being a byproduct from the meat industry. However, challenges such as low yields, high production costs, and ethical issues associated with animal-derived HA has driven the development of microbial production methods for HA.
Sources: en.wikipedia.org
=== Metabolism and excretion === Docetaxel is mainly metabolised in the liver by the cytochrome P450 CYP3A4 and CYP3A5 subfamilies of isoenzymes. Metabolism is principally oxidative and at the tert-butylpropionate side chain, resulting first in an alcohol docetaxel (M2), which is then cyclised to three further metabolites (M1, M3 and M4). M1 and M3 are two diastereomeric hydroxyoxazolidinones and M4 is an oxazolidinedione. Phase II trials of 577 patients showed docetaxel clearance is related to body surface area and to hepatic enzyme and alpha1 acid glycoprotein plasma levels. The following model represents docetaxel clearance in humans:
α-ketoglutarate + NH+4 ⇄ glutamate The α-ketoglutarate family of amino acid synthesis (synthesis of glutamate, glutamine, proline and arginine) begins with α-ketoglutarate, an intermediate in the Citric Acid Cycle. The concentration of α-ketoglutarate is dependent on the activity and metabolism within the cell along with the regulation of enzymatic activity. In E. coli citrate synthase, the enzyme involved in the condensation reaction initiating the Citric Acid Cycle is strongly inhibited by α-ketoglutarate feedback inhibition and can be inhibited by DPNH as well high concentrations of ATP. This is one of the initial regulations of the α-ketoglutarate family of amino acid synthesis. The regulation of the synthesis of glutamate from α-ketoglutarate is subject to regulatory control of the Citric Acid Cycle as well as mass action dependent on the concentrations of reactants involved due to the reversible nature of the transamination and glutamate dehydrogenase reactions. The conversion of glutamate to glutamine is regulated by glutamine synthetase (GS) and is a key step in nitrogen metabolism. This enzyme is regulated by at least four different mechanisms: 1. Repression and depression due to nitrogen levels; 2. Activation and inactivation due to enzymatic forms (taut and relaxed); 3. Cumulative feedback inhibition through end product metabolites; and 4. Alterations of the enzyme due to adenylation and deadenylation.
{\displaystyle {\begin{aligned}\int \delta \varepsilon &=\int _{L}^{l}{\frac {\delta l}{l}}\\\varepsilon &=\ln \left({\frac {l}{L}}\right)=\ln(\lambda )\\&=\ln(1+e)\\&=e-{\frac {e^{2}}{2}}+{\frac {e^{3}}{3}}-\cdots \end{aligned}}}
Cooper was orbiting the Earth every 88 minutes 45 seconds at an inclination of 32.55 degrees to the equator. His scheduled rest period was during orbits 9 through 13. He had a dinner of powdered roast beef mush and some water, took pictures of Asia and reported the spacecraft condition. Cooper was not sleepy and during orbit 9 took some of the best photos made during his flight. He took pictures of the Tibetan highlands and of the Himalayas.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.